118nok
0,0 %
Date:2025-07-16Time:18:00:00Latest report:Q4-2023List:Oslo BorsTicker:BGBIO
Market Cap:46 mnokEnterprise Value:-94 mnokNet Sales:0,85 mnokEarnings:-139,3 mnokEmployees:0ISIN:NO0013251173

Ratios

10-year key figure history for BerGenBio turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for BerGenBio with index and moving average MA50 and MA200.

Stockprice:1,18
MA50:1,53
MA200:5,42
Price/MA200:-78,2 %
RSI (14):25,6
Price/MA50:-22,6 %

Description

BerGenBio is a Norwegian oncology company. The company conducts research and development of inhibitory drugs for the treatment of aggressive types of cancer. The company has developed several products whose composition is intended to block the protein AXL, a protein positively related to the spread of cancer cells. The company was founded in 2007 and is headquartered in Bergen, Norway.

Biotechnology